Summary Twenty-four cases of histologically defined follicle centre cell (FCC) lymphoma have been examined for allele imbalance at 19 microsatellite loci spanning the length of chromosome 6, including six markers within the major histocompatibility complex (MHC), using fluorescent polymerase chain reaction (PCR) to amplify microsatellites. Nineteen cases were observed in which imbalance of one or more markers on chromosome 6 had occurred (79%). The frequency of allele imbalance was significantly higher on 6p than 6q, and two regions of deletions, 6p24-25 and 6p2l.3-23, were identified in which the loci showed a significantly high allele imbalance frequency.
Follicle centre cell lymphoma (FCC) as defined by the REAL classification, includes centroblastic/centrocytic lymphomas as defined by the Kiel classification, and a follicular small cleaved, follicular mixed small-and large-cell, and follicular predominantly large-cell lymphomas of the working formulation (Harris et al., 1994) . Recently, it has become apparent that almost all cases of FCC lymphoma possess a t(14:18) which leads to the deregulation of the bcl-2 gene (Korsmeyer, 1992) . The over-expression of this gene allows the neoplastic cell to escape the induction of apoptotic cell death, which is the fate of many germinal centre cells. Evidence from mice transgenic for Ig/bcl-2 has shown that lymphoproliferations, which were initially polyclonal, eventually become clonal, presumably because of additional genetic changes (Korsmeyer, 1992) .
The best example of how further genetic changes can influence clinical behaviour is illustrated by the transformation of FCC lymphomas to agressive high-grade tumours. In transgenic mice this transition is very frequently associated with deregulation of the myc oncogene, but this is only rarely seen in humans. In humans the most frequently seen lesions are mutations of the p53 gene, which have been documented in approximately 30% of cases (Sander et al., 1993) .
Despite this knowledge of transformed tumours, the nature of the events occurring in the genome early in the natural history of the condition, during the indolent clinical phase, is not known. A number of cytogenetic changes which occur in addition to the t(14;18) have been identified, among which are a number of translocations, deletions and duplications of specific chromosomal regions (Yunis et al., 1987) . These additional changes are more frequently seen in the tumours of higher pathological grade, according to the working formulation (Yunis et al., 1984) . One of the consistently ocurring cytogenetic abnormalities documented, in addition to the t(14;18), is deletion of portions of chromosome 6. This may play an important role in lymphoma progression (Schouten et al., 1990) , as it is seldom seen as the sole abnormality. The most common abnormality is a partial deletion of the q arm (Offit et al., 1993; Giadano et al., 1992) (Yandell and Dryja, 1989) , combined with fluorescent detection (Cawkwell et al., 1993 (Cawkwell et al., , 1994 
Materials and methods
We have used fluorescent PCR, the methodolgy for which has been published previously (Cawkwell et al., 1993 (Cawkwell et al., , 1994 Randerson et al., 1996) , to amplify a series of microsatellite markers which are distributed along the length of chromosome 6. In addition several markers were chosen which map Samples Formalin-fixed paraffin-embedded material from histologically defined cases of FCC lymphoma (where it was possible to obtain DNA from uninvolved tissue) were chosen for study. The DNA from uninvolved tissue provides normal somatic DNA with which to compare the tumour DNA. In the majority of cases this was obtained from mouthwashes. All of these cases had further sections cut, and the histological diagnosis was reviewed and reclassified according to the REAL classification (Harris et al., 1994) .
DNA was isolated by standard sodium dodecyl sulphate (SDS)/proteinase K phenol/chloroform extraction (Bell et al., 1991 (Gyapay et al., 1994) ; TNFa at 6p2l.3 (Nedospadov et al., 1991) ; and TAPI located within the third intron of the TAP1 gene (Carrington and Dean, 1994) . Three microsatellites, D6S248 at 6p2l, D6S260 at 6p12 (Weissenbach et al., 1992) , and D6S243 at 6qll-p21.1 (Orphanos et al., 1993) are centromeric of the MHC.
Seven markers on 6q were also studied: D6S286 at 6pll.l-qll lies close to the centromere although whether it is located on 6p or 6q is unclear; D6S300 at 6ql2-14; D6S262 at 6ql6; D6S279 at 6q21-23.3; D6S290 at 6q24 (Weissenbach et al., 1992) ; ESR which is linked to the oestrogen receptor gene at 6q24 (del Senno et al., 1993) ; D6S264 at 6q26; and D6S281 at 6q27, close to the telomere (Weissenbach et al., 1992) . The best estimation of the arrangement of the microsatellites in relation to each other and their distribution along the chromosome is shown in Figure 1 .
Eight tumour-suppressor gene loci (APC x 2, p53 x 2, DCC, WT, RBl, NM23) located on disparate chromosomes were also examined in each case (Cawkwell et al., 1994; Randerson et al., 1996) .
Primer synthesis Thirteen of the primer pairs were donated by J Todd, Oxford. Primers for D6S243, D6S248, D6S334, D6S291, D6S105, D6S265 and TAPI were synthesised in-house, on an ABI391 DNA synthesiser (Applied Biosystems, Foster City, CA, USA). Fluorescent primers were labelled with either, hex amidite, 6'-fam amidite or tet amidite fluorochrome (Cawkwell et al., 1994) .
Amplification of microsatellite markers PCR was performed using an initial denaturation step of 5 min, followed by 28 or 30 cycles of 95°C for 40 s, 55°C for 40 s and 72°C for 40 s. In the final round the extension at 72°C was maintained for 1.5 min. All PCR amplification was carried out in 1 xPCR buffer (10 mM Tris pH 9.1, 500 mM potassium chloride, 1.0% Triton X, 0.1% gelatin) containing 200 jiM dNTPs. Magnesium chloride concentration was optimised for each primer pair (1.5-2 mM). Twenty-five pmol of each primer and 1 unit of SuperTaq Taq polymerase (HT Biotechnology, Cambridge, UK) was used for each 25 ,ul reaction.
Analysis of amplified product
The amplified products were visualised following electrophoresis on a 6% polyacrylamide denaturing gel (Severn Biotech Ltd., Kidderminster, UK) in 1 x TBE buffer on a model 373A automated fluorescent DNA sequencer (Applied Biosystems). PCR product (1 pl) was combined with 4.5 pl formamide and 0.5 ,ul of a fluorescent size marker (GS2500P, Applied Biosystems) and denatured at 90°C for 3 min before loading on the gel. The gel was run for 7 h at 30W and 40°C.
The laser-excited fluorescent emission of the labelled PCR product, collected by the Genescan collection software during the run, was automatically analysed by the Genescan analysis program (Applied Biosystems) and used to construct a computerised gel image, individual PCR products being displayed as an electrophoretogram. Comparison with internal size standards allows the exact size and the relative quantity of a particular allele to be calculated.
Calculation of allele ratios Using this method, allele imbalance cannot be estimated by looking only at the tumour tissue, because the PCR amplification will vary unpredictably and comparison has to be made with normal uninvolved tissue. Even though PCR amplification may vary, the ratio between the two alleles in a heterozygous sample will remain constant. It is therefore possible to compare the ratio of tumour and normal DNA and to demonstrate allele imbalance. A 50% change in the ratio has been taken as indicating allele imbalance (Cawkwell et al., 1993 (Cawkwell et al., , 1994 (Figure 2 
Results
In order for the tumour -normal ratio (T/N) to be valid for assigning allele imbalance, the distribution of the ratio of the two alleles in the tumour samples (T1/T2) and the equivalent ratios in normal tissues (NI/N2) for each individual locus must be directly comparable. Paired t-tests comparing these ratios demonstrated no significant differences (P<0.005) at any of the markers in the study, showing that these distributions were comparable. In order to determine whether allele imbalance had occurred, on the basis of the tumour-normal ratio alone, it was necessary to determine a maximum value at which allele imbalance could be assigned. The distribution of tumour-normal ratios was plotted and was found to correspond to distributions published in previous studies, indicating a maximum value of 0.5 for _-_ markers with allele imbalance (Cawkwell et al., 1993; Soloman et al., 1987) . In order to visualise this further boxand-whisker plots of the distributions of tumour and normal ratios, for each locus, were constructed. This allowed outliers which fell at the extremes of the distribution range or greater than 1.5 times the interquartile range to be identified easily. These were found to correspond to the observed cases of allele imbalance (Figure 3) .
We have looked for allele imbalance at 19 markers located on chromosome 6 and the results are represented in Table I . Only five of the 24 cases had no evidence of allelic imbalance at any of the microsatellite markers. The frequency of imbalance was found to be significantly higher on 6p than 6q (P= 0.0018). This is surprising because cytogenetic studies have identified more frequent deletions of 6q. A Mann-Whitney-Wilcoxon comparison of the allele imbalance frequencies obtained on 6p and 6q, with the frequencies obtained using a panel of eight disparate tumour-suppressor (TS) gene microsatellites on the same sample DNA, showed that there was no significant difference of allele imbalance between loci on 6q and the TS gene loci (P = 0.817), but that there was a significant difference in allele imbalance between the 6p loci and the TS gene loci (P= 0.0026) . This suggests that the mean allele imbalance seen on 6q (11%) and the TS gene loci (11%) represents the background level of allele imbalance at any locus in FCC lymphoma. In order to map regions of allele imbalance and possible LOH, the frequency of allele imbalance at any one locus would need to be significantly higher than the background imbalance, i.e. fall outside the 95% confidence intervals for the background mean (11%). Using chi-squared tests to compare the frequency of allele imbalance at each locus with the background mean, a significant difference was found at seven loci on the p arm (P<0.05). D6S309 (47%, P<0.0001) and D6S277 (30%, P=0.0016) at 6p24-25, D6S344 (43%, P=0.0001) at 6p2l.3 -23 and D6S105 (28%, P=0.0043), D6S276 (38%, P<0.0001), D6S265 (29%, P=0.0027) and D6S291 (25%, P=0.0167) at 6p2l.3 within the MHC. This suggests that the regions 6p24-25 and 6p2l.3-23 may contain sites of genes important in the pathogenesis of FCC lymphoma. Although no allele imbalance frequencies on 6q are significantly higher than the background, region 6q23-25, which shows the highest frequency of imbalance on 6q, corresponds to the RCDs predicted from cytokinetic studies.
In individual patients it was possible to identify discrete regions of allele imbalance using this approach. In some instances a single region of imbalance involving several adjacent loci was seen. In other cases several non-adjacent loci showed imbalance, for example, case 17 where three disparate loci, D6S277, D6S276 and D6S300, on both the p and q arm demonstrate imbalance. Given the high incidence of imbalance which appears to be a general feature of FCC lymphoma, the apparent regions of imbalance may be owing to chance. This is more likely on those cases where several disparate loci demonstrate imbalance. In cases where several adjacent loci are affected, the regions of imbalance generally correspond to regions containing those loci with significantly high frequencies of allele imbalance (6p24-25 and 6p2l.3-23) or in the known RCDs on 6q (6q23 -27).
Discussion
We have attempted to identify regions of chromosome 6 which may be important in the pathogenesis of the indolent phase of FCC lymphoma, in addition to the deregulation of bcl-2. The majority of cases had an abnormality of chromosome 6. The highest frequency of allele imbalance was observed at loci in the regions 6p24-25 and 6p2l.3-23. These regions may represent the sites of genes which collaborate with bcl-2 in the indolent phase. However, 6p24-25 is very close to the telomere and the high frequency of allele imbalance may reflect this. When interpreting the Chromosome 6 in FCC lymphoma J Randerson et a! * 945 results of such a study, it is of crucial importance to consider what constitutes a significant frequency of change at a particular locus. In colon cancer, frequencies of allele loss of up to 70% can be seen for p53 and DCC. None of the changes we have seen reach these levels. In transformed FCC lymphoma, the frequency of p53 mutations of 30% is taken as indicating a significant involvement in the transformation process (Sander et al., 1993 ), and we have described a number of loci where imbalance reaches this frequency. By analysing the frequency of LOH at every locus, it has been possible to identify the background rate of LOH as 11%. With this figure it is then possible to ask the question, whether change at any one locus differs significantly from the mean. Using this approach a number of regions have been identified where LOH occurs significantly more frequently (P<0.05) (Figure 1) .
We have looked carefully at the MHC (6p2l.3), a region which has been shown to be deleted in ovarian cancer (Foulkes et al., 1993) . In these and other tumours, it has been suggested that such deletions may allow the tumour to escape immunosurveillance and such a mechanism could easily be envisaged to be acting during the indolent phase of FCC lymphoma. Four of the seven loci within the MHC showed a significantly high frequency of allele imbalance, although in only one case was the frequency of deletion greater than 30%. Other genes which may be involved in this region are the tumour factor necrosis genes A and B, and the octomer binding transcription factor OTF3. Region 6p24-25 contains the gene for the AP-2 transcription factor and other genes of interest in the region 6p21.3-25 include a neuroblastoma ras viral oncogene homologue Nras3, ITPR3 the receptor for the inositol 1,4,5-triphosphate involved in cell signalling, and PCNAL a putative proliferating cell nuclear antigen.
Imbalance of 6q was identified at a significantly lower frequency than on 6p, but the regions with imbalance correspond to previously identified cytogenetic deletions. The highest frequency of imbalance on 6q was at D6S300 (20%), but was not significantly different to the background. The low frequency of change observed on 6q would suggest that in FCC lymphoma, certainly during the indolent clinical phase, this region is not pathologically important. This reinforces the suggestion that abnormalities of 6q are associated with lymphomas which have progressed to a more aggressive disease.
The detection of microsatellites by polymerase chain reaction coupled with fluorescent detection has enabled us to look at chromosome 6 on formalin-fixed paraffinembedded material. This technique is more sensitive than any of the currently available methods for carrying out LOH studies and permits the mapping of submicroscopic regions of imbalance in the presence of infiltrating normal tissue. This is particularly important in disease where microdissection of disease tissue is difficult. We have been able to identify two regions of allele imbalance on chromosome 6 in cases of FCC lymphoma, although mapping the exact boundaries of the region has not been possible. This is owing to the fact that in over a quarter of cases the boundary markers have been uninformative, and that the markers involved in this study are still a long distance apart. In order to map the extent of the region more accurately a saturation study of more microsatellite markers located at the boundaries of the region is required.
We seem to have identified two regions on 6p which have significantly higher rates of LOH than seen on the background. The pathogenetic importance is however difficult to ascertain. These results show that in a cell immortalised as a result of bcl-2 deregulation, there is a surprisingly high incidence of genetic stability. These cells are mature, well differentiated and have few cytogenetic abnormalities in addition to a t(14;18), which is in marked contrast to epithelial malignancies. The nature history of these tumours is to transform to a clinically aggressive lymphoma in a high proportion of cases.
The finding of a high background rate of LOH is perhaps 946 not surprising as these cells will be resistant to apoptosis as a result of Bcl-2 expression. Random genetic lesions will not therefore be deleted by loss of that clone as a result of programmed cell death. These random changes will, therefore. continue to accumulate over the natural history of the disease at diverse chromosome loci. When critical genes are deleted. transformation to a high grade will occur. One such event will be abnormalities of p53. the most common event associated with transformation. The question may then arise as to whether other such genes may be identified. It seems unlikely that any single gene will be responsible for transformation. and the reason that p53 abnormalities are found so frequently is that rather than being directly responsible for transformation themselves, they merely allow the more rapid emergence of other collaborating genetic abnormalities.
